DREAMM-20 Hints at a More Tolerable Path for BCMA-Targeted Therapy in Myeloma

The International Myeloma Foundation Proudly Announces EMA-CHMP Positive Qualification Advice ...

STUDIO CITY, Calif., July 02, 2025 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) and the collaborative stakeholder group i2TEAMM (International Independent Team for Endpoint Approval of Myeloma MRD), which includes top global myeloma experts, proudly announce the positive outcome…

DREAMM-20 Hints at a More Tolerable Path for BCMA-Targeted Therapy in Myeloma

(MedPage Today) -- At the recent American Society of Clinical Oncology (ASCO) meeting, early data from the DREAMM-20 trial showed that the naked B-cell maturation antigen (BCMA)-targeted monoclonal antibody belantamab -- without the cytotoxic...

EU panel backs 1st-line Sarclisa for transplant-eligible myeloma

A European Medicines Agency committee has recommended that Sarclisa (isatuximab), used in combination with standard-of-care medications, be approved for the treatment of adults newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The European Commission will consider the opinion from the Committee for Medicinal Products for Human Use (CHMP) when making a final approval decision in the coming months. Sarclisa, from S…

Prophylactic Tocilizumab and Sequencing Strategies in the Bispecific Era

A panelist discusses the evolving role of prophylactic tocilizumab in reducing cytokine release syndrome during bispecific antibody therapy, enabling outpatient treatment and improving patient experience, while highlighting the importance of timing and sequencing T-cell–targeting therapies to optimize efficacy and immune recovery in multiple myeloma management.

Treatment Overview of Transplant-Eligible Newly Diagnosed Multiple Myeloma

Panelists discuss the adoption of 4-drug regimens—including a CD38 monoclonal antibody—as the standard frontline therapy for patients with transplant-eligible multiple myeloma, emphasizing tailored modifications based on age and frailty, and evolving maintenance strategies that incorporate daratumumab to deepen and sustain responses post-transplant.

Introduction and Overview of Multiple Myeloma

The program emphasizes the importance of incorporating patient and caregiver perspectives alongside clinical expertise to support personalized, empathetic care and shared decision-making in managing the diverse and complex challenges of multiple myeloma.